Rachel Yost
About Rachel Yost
Rachel Yost is the Associate Director of Cell Therapy MS&T at Bristol Myers Squibb, with over a decade of experience in the biopharmaceutical industry focusing on cell therapy and process engineering.
Current Role at Bristol Myers Squibb
Rachel Yost holds the position of Associate Director, Cell Therapy MS&T at Bristol Myers Squibb. In this role, she focuses on the development and oversight of cell therapy processes, leveraging her extensive background in biopharmaceuticals. Rachel contributes to the strategic planning and execution of cell therapy manufacturing projects, ensuring high standards of quality and efficiency.
Previous Experience at Bristol Myers Squibb
Before her current role, Rachel Yost worked as Principal Engineer, Early Phase Drug Product Technical Steward at Bristol Myers Squibb from 2020 to 2021. In this capacity, she played a crucial role in early-phase drug product development, providing technical oversight and ensuring the successful transition from development to manufacturing.
Experience at Juno Therapeutics, Inc.
Rachel Yost's tenure at Juno Therapeutics, Inc. spanned from 2014 to 2020, during which she held several roles. She started as a Process Engineer, eventually advancing to Senior Process Engineer. Rachel was instrumental in developing and optimizing cell therapy processes and was based predominantly in the Greater Seattle Area. Her work significantly contributed to the company's mission of bringing innovative cell therapy treatments to market.
Early Career at Merck and McNeil Consumer Healthcare
Rachel Yost worked at Merck as an Associate Specialist, Engineering, from 2012 to 2014 in Durham, NC. There she contributed to pharmaceutical manufacturing processes. Prior to that, she gained experience as an R&D Co-Op at McNeil Consumer Healthcare from 2011 to 2012. Her roles at these companies laid the foundation for her expertise in engineering and process development in the healthcare industry.
Educational Background and Degree
Rachel Yost earned her Bachelor of Science (B.S.) in Bioengineering from Penn State University, where she studied from 2008 to 2012. Her education provided a strong foundation in bioengineering principles, which she has applied throughout her career in the biopharmaceutical industry. Rachel's academic background has been crucial to her successful contributions to cell therapy and process engineering.